Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activity that Counteracts Cognitive Decline in a Mouse Model of Psychiatric Disorders.
KS-133
VIPR2/VPAC2
antagonist
bicyclization
cyclic peptide
schizophrenia
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
08
2021
accepted:
11
10
2021
entrez:
25
11
2021
pubmed:
26
11
2021
medline:
26
11
2021
Statut:
epublish
Résumé
Worldwide, more than 20 million people suffer from schizophrenia, but effective and definitive new therapeutic drugs/treatments have not been established. Vasoactive intestinal peptide receptor 2 (VIPR2) might be an attractive drug target for the treatment of schizophrenia because both preclinical and clinical studies have demonstrated a strong link between high expression/overactivation of VIPR2 and schizophrenia. Nevertheless, VIPR2-targeting drugs are not yet available. VIPR2 is a class-B G protein-coupled receptor that possesses high structural homology to its subtypes, vasoactive intestinal peptide receptor 1 (VIPR1) and pituitary adenylate cyclase-activating polypeptide type-1 receptor (PAC1). These biological and structural properties have made it difficult to discover small molecule drugs against VIPR2. In 2018, cyclic peptide VIpep-3, a VIPR2-selective antagonist, was reported. The aim of this study was to generate a VIpep-3 derivative for
Identifiants
pubmed: 34819858
doi: 10.3389/fphar.2021.751587
pii: 751587
pmc: PMC8607231
doi:
Types de publication
Journal Article
Langues
eng
Pagination
751587Informations de copyright
Copyright © 2021 Sakamoto, Chen, Miyaoka, Yamada, Masutani, Ishimoto, Hino, Nakagawa, Asano and Ago.
Déclaration de conflit d'intérêts
KS and TEM are full‐time employees of Ichimaru Pharcos Co. Ltd. The authors declare that this study received funding from Ichimaru Pharcos Co. Ltd. The funder had the following involvement in the study: the study design, interpretation of data, the writing of this article and the decision to submit it for publication. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Neurobiol. 2018 Nov;55(11):8263-8277
pubmed: 29526016
Theranostics. 2018 Feb 5;8(6):1481-1493
pubmed: 29556336
J Neuroendocrinol. 2007 May;19(5):321-7
pubmed: 17425606
Diabetes. 2002 May;51(5):1453-60
pubmed: 11978642
J Biol Chem. 2003 Mar 21;278(12):10273-81
pubmed: 12525492
Br J Pharmacol. 2015 Jul;172(13):3189-93
pubmed: 25964986
Dev Neurosci. 2002;24(1):14-23
pubmed: 12145407
Nature. 2011 Mar 24;471(7339):499-503
pubmed: 21346763
Mol Neurobiol. 2017 Nov;54(9):7019-7027
pubmed: 27796743
J Pharmacol Exp Ther. 2002 Sep;302(3):1062-9
pubmed: 12183664
Br J Pharmacol. 2012 May;166(1):4-17
pubmed: 22289055
Br J Pharmacol. 2013 Jun;169(3):512-23
pubmed: 23517078
Cell. 2002 May 17;109(4):497-508
pubmed: 12086606
Front Neurosci. 2021 Jul 22;15:717490
pubmed: 34366784
Neurosci Lett. 2020 May 1;726:133664
pubmed: 29966749
Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):579-90
pubmed: 18172612
Brain Behav Immun. 2015 Feb;44:167-175
pubmed: 25305591
Am J Psychiatry. 2004 Apr;161(4):742-4
pubmed: 15056523
Mol Psychiatry. 2010 Aug;15(8):823-30
pubmed: 20065955
J Cereb Blood Flow Metab. 2006 Jan;26(1):58-67
pubmed: 15959462
J Comp Neurol. 2012 Aug 15;520(12):2730-41
pubmed: 22684939
Neuropsychopharmacology. 2010 May;35(6):1279-89
pubmed: 20072116
Biol Psychiatry. 2016 Aug 15;80(4):331-337
pubmed: 26795442
Biol Psychiatry. 2004 Jun 15;55(12):1128-37
pubmed: 15184031
Am J Psychiatry. 2011 Mar;168(3):302-16
pubmed: 21285140
Neuroreport. 2000 Nov 9;11(16):3621-5
pubmed: 11095531
Schizophr Bull. 2000;26(1):119-36
pubmed: 10755673
Assay Drug Dev Technol. 2002 Nov;1(1 Pt 1):97-104
pubmed: 15090161
Pharm Res. 2019 Apr 1;36(5):76
pubmed: 30937626
Biochim Biophys Acta. 2011 May;1814(5):724-30
pubmed: 21439408
Arch Gen Psychiatry. 2000 Jan;57(1):65-73
pubmed: 10632234
Front Endocrinol (Lausanne). 2021 Jan 20;11:585082
pubmed: 33551991
Curr Pharm Des. 2004;10(12):1325-40
pubmed: 15134484
Peptides. 2007 Sep;28(9):1631-9
pubmed: 17574305
Neurobiol Learn Mem. 2017 Nov;145:222-231
pubmed: 29030297
Nat Commun. 2020 Jul 7;11(1):3394
pubmed: 32636383
Peptides. 1997;18(10):1547-54
pubmed: 9437715
Neuroscience. 2004;127(2):481-96
pubmed: 15262337
J Pharm Sci. 1987 Jul;76(7):535-40
pubmed: 2889824
ACS Med Chem Lett. 2013 Oct 16;4(12):1163-8
pubmed: 24900623
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1973-1979
pubmed: 30077368
Neuropsychiatr Dis Treat. 2006 Dec;2(4):531-6
pubmed: 19412501
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
Pharmacol Rev. 2009 Sep;61(3):283-357
pubmed: 19805477
Schizophr Bull. 1998;24(3):425-35
pubmed: 9718634
Mol Pharmacol. 2010 Jan;77(1):95-101
pubmed: 19854890
J Neurochem. 1996 Apr;66(4):1762-5
pubmed: 8627335
NPJ Schizophr. 2021 Mar 18;7(1):20
pubmed: 33737508
Neuropsychopharmacology. 2003 Mar;28(3):599-609
pubmed: 12629543
Front Endocrinol (Lausanne). 2012 Nov 16;3:139
pubmed: 23162538
J Child Psychol Psychiatry. 2016 Feb;57(2):152-60
pubmed: 26304033
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11575-80
pubmed: 11027354
Psychopharmacology (Berl). 2015 Jun;232(12):2181-9
pubmed: 25575489
Adv Drug Deliv Rev. 2012 May 15;64(7):614-28
pubmed: 22119441
Front Psychiatry. 2017 May 23;8:83
pubmed: 28588507
Autism Res. 2016 Sep;9(9):926-39
pubmed: 26714434
Curr Pharm Des. 2011;17(10):1036-9
pubmed: 21524251
Eur J Neurosci. 2003 Jan;17(2):197-204
pubmed: 12542655
J Comp Neurol. 1997 Oct 6;386(4):661-80
pubmed: 9378859
Front Neurosci. 2020 Jun 04;14:521
pubmed: 32581681
CNS Neurol Disord Drug Targets. 2010 Nov;9(5):661-6
pubmed: 20632962
Pharmacol Biochem Behav. 2014 Nov;126:43-9
pubmed: 25240644
Peptides. 1997;18(3):403-8
pubmed: 9145428
Schizophr Res. 2014 Jun;156(1):66-70
pubmed: 24794882
J Comp Neurol. 2004 Aug 30;476(4):388-413
pubmed: 15282712
JAMA Psychiatry. 2014 Dec 1;71(12):1323-31
pubmed: 25271938
J Mol Neurosci. 2018 Sep;66(1):102-113
pubmed: 30105629
Schizophr Res. 2002 Nov 1;58(1):75-81
pubmed: 12363393
Mol Psychiatry. 2019 Dec;24(12):1884-1901
pubmed: 31444475
Front Cell Neurosci. 2020 Jul 17;14:221
pubmed: 32765225
Neural Plast. 2015;2015:708306
pubmed: 26075104
Ann N Y Acad Sci. 2008 Nov;1144:28-35
pubmed: 19076360
Biochem Pharmacol. 2011 Feb 15;81(4):552-61
pubmed: 21114961
Trends Pharmacol Sci. 2014 Jan;35(1):12-22
pubmed: 24359917